Personal Lab Offers Rapid Detection of Food Allergens
|
By LabMedica International staff writers Posted on 06 Nov 2017 |

Image: The iEAT system for onsite antigen detection consists of a pocket-sized detector, an electrode chip, and a disposable kit for allergen extraction. The detector connects with a smartphone for system control and data upload to a cloud server (Photo courtesy of Lin, et al. ACS Nano, August 2017).
Researchers have developed a small, low cost device for individual use that can accurately detect food allergens in less than ten minutes.
Adverse food reactions, including food allergies, food sensitivities, and autoimmune reaction (e.g., celiac disease) affect 5-15% of the population of the USA and remain a considerable public health problem requiring stringent food avoidance and epinephrine availability for emergency events. Avoiding problematic foods is difficult in practical terms, given current reliance on prepared foods and out-of-home meals.
In response to the food allergy problem, investigators at Harvard Medical School (Boston, MA, USA) developed a portable, point-of-use detection technology, that they called "integrated exogenous antigen testing" (iEAT).
The iEAT device consists of three components: (1) a small plastic test tube, (2) a small electronic detection module, and (3) the electronic keychain reader. To perform the test, the user dissolves a small sample of the food in the plastic test tube and then adds magnetic beads that capture the food allergen of interest. A bit of this mixture is loaded onto electrode strips attached to a small module that is then inserted into the electronic keychain reader. The keychain reader has a small display that indicates whether the allergen is present, and if so, in what concentration.
The prototype iEAT system was optimized to detect five major food antigens in peanuts, hazelnuts, wheat, milk, and eggs. Antigen extraction and detection with iEAT required less than 10 minutes and achieved high-detection sensitivities (e.g., 0.1 milligram per kilogram for gluten, 200 times lower than regulatory limits of 20 milligram per kilogram).
The investigators also developed a dedicated cell phone application, which allows the user to compile and store the data collected by testing different foods for various allergens at different restaurants or in packaged foods. The application is set up to share this information online with both time and location stamps indicating when, where, and in what food or dish an allergen reading was taken.
“High accuracy built into a compact system was the key goals of the project,” said contributing author Dr. Ralph Weissleder, professor of radiology and systems biology at Harvard Medical School. “Users can be confident that even if they are sensitive to very low levels, iEAT will be able to give them exact concentrations. Armed with accurate concentration levels they will not have to completely avoid potentially problematic foods, but will know whether an allergen is at a dangerous level for them or a concentration that is safe for them to eat.”
The iEAT device was described in the August 2017 issue of the journal ACS Nano.
Related Links:
Harvard Medical School
Adverse food reactions, including food allergies, food sensitivities, and autoimmune reaction (e.g., celiac disease) affect 5-15% of the population of the USA and remain a considerable public health problem requiring stringent food avoidance and epinephrine availability for emergency events. Avoiding problematic foods is difficult in practical terms, given current reliance on prepared foods and out-of-home meals.
In response to the food allergy problem, investigators at Harvard Medical School (Boston, MA, USA) developed a portable, point-of-use detection technology, that they called "integrated exogenous antigen testing" (iEAT).
The iEAT device consists of three components: (1) a small plastic test tube, (2) a small electronic detection module, and (3) the electronic keychain reader. To perform the test, the user dissolves a small sample of the food in the plastic test tube and then adds magnetic beads that capture the food allergen of interest. A bit of this mixture is loaded onto electrode strips attached to a small module that is then inserted into the electronic keychain reader. The keychain reader has a small display that indicates whether the allergen is present, and if so, in what concentration.
The prototype iEAT system was optimized to detect five major food antigens in peanuts, hazelnuts, wheat, milk, and eggs. Antigen extraction and detection with iEAT required less than 10 minutes and achieved high-detection sensitivities (e.g., 0.1 milligram per kilogram for gluten, 200 times lower than regulatory limits of 20 milligram per kilogram).
The investigators also developed a dedicated cell phone application, which allows the user to compile and store the data collected by testing different foods for various allergens at different restaurants or in packaged foods. The application is set up to share this information online with both time and location stamps indicating when, where, and in what food or dish an allergen reading was taken.
“High accuracy built into a compact system was the key goals of the project,” said contributing author Dr. Ralph Weissleder, professor of radiology and systems biology at Harvard Medical School. “Users can be confident that even if they are sensitive to very low levels, iEAT will be able to give them exact concentrations. Armed with accurate concentration levels they will not have to completely avoid potentially problematic foods, but will know whether an allergen is at a dangerous level for them or a concentration that is safe for them to eat.”
The iEAT device was described in the August 2017 issue of the journal ACS Nano.
Related Links:
Harvard Medical School
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







